Skip to main content
OpenTrials
Completed

NCT Number: NCT02430909

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

The purpose of this study is to evaluate the safety, efficacy and body distribution of Bimekizumab (UCB4940) when added to Certolizumab Pegol treatment in patients with Rheumatoid Arthritis. Neither the patient nor the doctor will know the treatment group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Ra0123 101, Prague, Czechia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To be eligible to participate in this study, all of the following criteria must be met:

  • Subject is informed and given approved written Informed Consent Form (ICF).
  • Subject is considered reliable and capable of adhering to the protocol.
  • Subject must have a diagnosis of adult-onset moderate-to-severe RA of at least 6 months' duration as defined by ACR/EULAR 2010 classification criteria.
  • Subject must have:
  • ≥6 tender joints (out of 68)
  • ≥6 swollen joints (out of 66)
  • CRP≥10.0mg/L .
  • Subject must have had inadequate response to at least 1 synthetic DMARD.
  • Subject is at least 18 years and less than 70 years of age at Visit 1 (Screening).
  • Female subjects must either be:
  • postmenopausal
  • permanently sterilized or,
  • if of childbearing potential, must be willing to use at least 2 effective methods of contraception,
  • Male subjects with partners of childbearing potential must be willing to use a condom when sexually active, during the study and for 5 months after last administration of study drug.

Exclusion criteria

Subjects are not permitted to enroll in the study if any of the following criteria is met:

  • Subject has previously participated in this study or has previously been assigned to treatment in a study of the investigational medicinal product (IMP) under investigation in this study (UCB4940 and/or CZP).
  • Subject has a history or active systemic/respiratory infection due to fungal, parasitic, or mycotic pathogens.
  • Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent TB infection are excluded.
  • Subject is at high risk of infection.
  • Subject has an active infection or has had a serious infection within 12 weeks prior to the first dose of study drug at Week 0.
  • Subject has renal or liver impairment.
  • Subject has a current or past history of gastrointestinal ulceration.
  • Subject has active neoplastic disease or history of neoplastic disease.
  • Subject has a concomitant diagnosis of any other inflammatory condition.
  • Subject has a secondary, non-inflammatory condition or a known diagnosis of fibromyalgia.

Treatment and study plan

Bimekizumab

Biological
  • Pharmaceutical form: Solution for infusion
  • Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose
  • Route of administration: iv infustion

Certolizumab Pegol

Biological
  • Pharmaceutical form: Prefilled syringes
  • Concentration: 200 mg/ml
  • Route of administration: Subcutaneous injection

Placebo

Other
  • Pharmaceutical form: Solution for infusion
  • Concentration: 0.9% saline
  • Route of administration: Intravenous infusion

Primary outcomes

  1. Incidence of Adverse Events

    Time frame: Screening (D-28) until final study visit (Week 44)

    All adverse events (AEs) are recorded during the entire study period.

  2. Change from Baseline 2 in DAS28(CRP)

    Time frame: Week 20

    DAS28 (Disease Activity Score 28) is a measure of disease activity in Rheumatoid Arthritis (RA) and is a composite score derived from the number of swollen and tender joints (out of 28), the CRP value and the patient global assessment of disease activity.

Secondary outcomes

  1. Percent improvement in ACR (American College of Rheumatology) criteria (ACRn) based on Baseline 2

    Time frame: Week 20

    ACRn is the percentage improvement from Baseline 2 in the number of tender joints, in the number of swollen joints, and in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).

  2. ACR20 response based on Baseline 2

    Time frame: Week 20

    The assessments are based on a 20% or greater improvement from Baseline 2 in the number of tender joints, in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).

  3. ACR50 response based on Baseline 2

    Time frame: Week 20

    The assessments are based on a 20% or greater improvement from Baseline 2 in the number of tender joints, in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).

  4. ACR70 response based on Baseline 2

    Time frame: Week 20

    The assessments are based on a 20% or greater improvement from Baseline 2 in the number of tender joints, in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).

  5. DAS28(CRP) remission

    Time frame: Week 20

    DAS28(CRP) remission is defined as DAS28(CRP) < 2.6. DAS28 is a measure of disease activity in RA and is a composite score derived from the number of swollen and tender joints (out of 28) , the C-reactive protein value and the patient global assessment of disease activity.

Sponsors and collaborators

Lead sponsor

UCB Celltech

Industry

Collaborators

  • PRA Health Sciences

Registry information

Official study title

A Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of UCB4940 Administered as Add-on to Certolizumab Pegol Therapy in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Apr 30, 2015
Registry last updated
May 31, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.